RxDoctor Payments Data

Holly Berndt, MD

Internal Medicine · Bristol, TNNPI 1528274859

Payments from drug & device makers

$618in general payments, 2019–2025

Across 37 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$102
  • Boehringer Ingelheim$54
  • Sun Pharmaceutical Industries Inc.$52
  • AbbVie$50
  • Jazz Pharmaceuticals Inc.$39
  • Shire North American Group Inc$35
  • plus $286 from 15 others

What the payments were for

  • Food & beverage$618100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$618 in reported general payments places this provider in the 60th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$67,810
Medicare patients
242
Services billed
604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban714$166,741
LinzessLinaclotide81$47,609
Invega SustennaPaliperidone Palmitate12$43,687
JardianceEmpagliflozin79$16,374
ErtapenemErtapenem Sodium31$12,788
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog73$12,557
TrulicityDulaglutide36$12,220
Levothyroxine Sodium1,293$11,200
EntrestoSacubitril/Valsartan79$10,383
VraylarCariprazine Hcl15$8,672
Sucralfate299$8,666
PremarinEstrogens, Conjugated18$8,654
Incruse ElliptaUmeclidinium Bromide30$8,572
Budesonide46$8,549
XifaxanRifaximin11$8,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$12$175,396732 claims
AbbVieLinzess, Vraylar$50$56,28296 claims
Boehringer IngelheimJardiance, Combivent Respimat, Trijardy Xr$54$31,293124 claims
GSKIncruse Ellipta, Arexvy, Anoro Ellipta$27$24,51770 claims
NovartisEntresto$23$10,38379 claims
MerckJanuvia$15$6,68243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Bristol

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →